文档介绍：化疗联合西妥昔单抗治疗大肠癌肝转移效果观察
何小进1,马进安2
;
,湖南长沙410011
【摘要】目的探讨西妥昔单抗联合化疗治疗大肠癌肝转移的疗效和不良反应。方法对30例转移性大肠癌患者应用西妥昔单抗联合奥沙利铂∕5-FU∕FA化疗联合方案进行治疗,每周一次维持,完成6周用药,评价药物的近期疗效及毒副作用。结果 30例患者均完成西妥昔单抗连续6周用药,奥沙利铂∕5-FU∕FA化疗2周期,无CR病例,6例PR(20%),10例SD(%),14例PD(%),%。本组30患者经西妥昔单抗联合化疗后,发生1级皮疹15例,2级皮疹7例,低热4例,肝功能转氨酶升高4例,无结膜炎及腹泻发生。且骨髓反应毒应在联合应用西妥昔单抗下未增加,经对症处理后以上不良反应患者均可耐受。结论西妥昔单抗联合化疗治疗肝转移性大肠癌近期疗效显著,可提高肿瘤对放化疗的敏感性。不良反应可以耐受。
关键词:结直肠癌;西妥昔单抗;化疗
[Abstract] Objective To investigate bined with chemotherapy for liver metastases of colorectal cancer efficacy and adverse reactions. Methods 30 patients with metastatic colorectal cancer patients with cetuximab plus oxaliplatin / 5-FU/FA chemotherapy treatment program once a week to maintain, complete the 6 weeks treatment, the evaluation of drug efficacy and side effects . Results 30 pleted cetuximab treatment for 6 weeks, oxaliplatin / 5-FU/FA 2 cycles of chemotherapy, patients without CR, 6 PR (20%), 10 例 SD (%), 14 cases of PD (%), disease control rate of %. The group of 30 patients with cetuximab bination with chemotherapy, the occurrence of a rash in 15 cases, 2 rash in 7 cases, fever in 4 cases, 4 cases of elevated liver transaminases, no conjunctivitis and diarrhea. And bone marrow toxic reaction should not, under cetuximab increased by more than symptomatic treatment in patients with adverse react